Case report: Confirming a diagnosis of severe olmesartan-associated enteropathy - 28/07/22
Doi : 10.1016/j.therap.2022.06.001
Lucien Roulet a, ⁎ 
, Lucia Bedatsova b, Laurent Merz c, Jules Desmeules d, Lila Saiah b
, Lucia Bedatsova b, Laurent Merz c, Jules Desmeules d, Lila Saiah b a Division of Clinical Pharmacy, Hospital Pharmacy of Nord Vaudois and Broye Region, 1400 Yverdon-les-Bains, Switzerland
b Treatment and Rehabilitation Centre, Hospitals of Nord Vaudois, 1436 Chamblon, Switzerland
c Division of Internal Medicine, Hospitals of Nord Vaudois, 1318 Pompaples, Switzerland
d Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Emergency Medicine and Intensive Care, Geneva University Hospitals and Geneva University, 1205 Geneva, Switzerland
⁎Corresponding author.
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Thursday 28 July 2022
This article has been published in an issue click here to access
This article has been published in an issue click here to access
Keywords : Olmesartan, Angiotensin II receptor blocker, Sprue-like enteropathy, Hospitalisation, Rechallenge
El texto completo de este artículo está disponible en PDF.
Esquema
| ☆ | This case has been declared to the Swiss Agency for Therapeutic Products (Lausanne, SMCELVIS-2021-08-18-273127) on 18 August 2021. |
© 2022
Société française de pharmacologie et de thérapeutique. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?